Atlas Trials

A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

Clinical trial NCT03978520 · COMPLETED

Trial details

NCT number
NCT03978520
Sponsor
AbbVie
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Systemic Lupus Erythematosus (SLE)
Start date
2019-07-25
Primary completion
2022-01-19
Enrollment
341

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.